$Trevi Therapeutics(TRVI.US)Haduvio 是 Trevi Therapeutics 的核心药物， 针对未满足的临床需求尤其是慢性咳嗽和慢性瘙痒。
其中慢性咳嗽（特发性肺纤维化相关慢性咳嗽），全球慢性咳嗽治疗市场预计到 2030 年可能达到 80 亿美元规模。
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.